United Therapeutics Put a Rare-Drug Pipeline on Varda's Orbital Platform. Now the Company Needs a Workforce That Doesn't Exist Yet.

The Sixth Reentry: From Proof-of-Concept to Production Cadence

On May 20, 2026, a Varda capsule parachuted onto the Koonibba Test Range in South Australia. It was the company's sixth successful reentry and the fourth capsule to land at that site in 15 months. The W-6 mission had launched March 30 on a SpaceX Transporter-16 rideshare, spent weeks in orbit, then came back through the atmosphere on its own.

That cadence is the point. Varda's W-Series capsules are free flyers: self-sustaining, independent of any space station, built to bring materials back to Earth. The company manufactures the heatshields at its El Segundo headquarters using C-PICA, an ablative material originally developed at NASA's Ames Research Center. Every W-series capsule has used it.

W-6 carried three payloads. Rhea Space Activity flew an autonomous navigation system that used onboard imagery of stars and low Earth orbit satellites to fix the capsule's position during hypersonic reentry. Sandia National Laboratory contributed a nose tile embedded with temperature sensors to compare real-world heating against models. NASA Ames flew two instrumented shoulder tiles built with an alternative production technique called eChar. The Air Force Research Laboratory funded the mission through its Prometheus program, which uses commercial spacecraft as a low-cost hypersonic testbed.

Dave McFarland, Varda's vice president of hypersonic test and targets, said the data from this mission would have taken years to collect through traditional methods. CEO Will Bruey put it more bluntly at the ASCEND conference May 20: the company buys delta-v cheap from Falcon 9 and sells it into a market used to paying for dedicated launches.

The defense revenue is not a side business. Bruey estimated 80% of Varda's capital has gone into the spacecraft assembly line, with 20% into the pharma lab. Every capsule off that line can fly either a commercial pharma mission or a defense payload. That dual-use flexibility funds the production rate, and production rate is what turns orbital manufacturing from a science project into something a workforce can build a career on.

Zero G Talent's board lists 19 open Varda roles added in the past 7 days, spanning mission operations, embedded software, and ground systems engineering in El Segundo. The capsules are flying. Now the company needs people to fly more of them.

United Therapeutics Signs On as Orbital Pharma's First Anchor Tenant

On May 13, 2026, Varda Space Industries announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore microgravity-based formulations of treatments for rare pulmonary disease. The partnership gives Varda something it lacked: a credible pharmaceutical anchor tenant willing to put real compounds on its orbital platform.

The deal matters because the orbital-manufact holds if someone actually wants to manufacture in orbit. Varda has now demonstrated six successful autonomous reentries. The hardware works. But hardware without a paying pharma partner is just a very expensive hobby. United Therapeutics, a company founded by CEO Martine Rothblatt to find treatments for pulmonary arterial hypertension, brings a commercial pipeline and decades of regulatory experience. It's the difference between a space station experiment and an industrial contract.

The collaboration will process small-molecule medicines for pulmonary disease aboard Varda's orbital platform during multiple missions to low Earth orbit. The companies plan to exploit microgravity's effect on crystal structures. On Earth, convection and sedimentation can disrupt uniform molecular assembly, while the absence of both in orbit lets molecules form more ordered, stable lattices. The target outcomes: better bioavailability, longer shelf life, reduced cold-chain dependence, and novel delivery formats like inhaled or controlled-release therapies. Varda's chief science officer Adrian Radocea framed it as combining United Therapeutics' drug-development expertise with "designs and processes not available under terrestrial conditions."

For the workforce angle, the deal is the inflection point. Bruey said the collaboration "strives to pioneer a new era in clinical development by completing the bridge from microgravity science to patient benefit on Earth." Rothblatt's own framing was more specific: the partnership will explore how space-based manufacturing could produce "significant improvements for rare pulmonary disease treatments." A company of United Therapeutics' scale doesn't sign research collaborations as a favor. It signs them when the science looks like it could translate into products.

That translation pipeline is what makes hiring for orbital manufacturing a real bet rather than a speculative one. The open roles on Varda's board span Space Mission Operations Engineer to Senior Space Embedded Software Engineer. These aren't research positions waiting for a grant cycle. They're the hiring cadence of a company that has a partner, a platform, and a reentry record, and needs people to turn proof-of-concept into production rhythm.

$187M Series C Backs the Orbital Factory Thesis

Varda Space Industries raised $187 million in a Series C round on July 10, 2025, bringing the El Segundo-based company's total capital raised to $329 million. The round was co-led by Natural Capital and Shrug Capital, with participation from Founders Fund, Peter Thiel, Khosla Ventures, Lux Capital, Caffeinated Capital, and Also Capital.

The raise came alongside two signals that Varda is transitioning from an experimental venture to an industrial one. The company had just completed its fifth successful reentry mission and announced the United Therapeutics collaboration, which gave the round a commercial anchor rather than a purely technical story. CNBC reported that Bruey told Morgan Brennan's "Manifest Space" podcast the Series C would fund two things: higher flight cadence and the buildout of a biologics lab to screen and prepare drug formulations for orbit.

Natural Capital's Ravi Tanuku, who joined Varda's board with the raise, wrote on LinkedIn that the firm sits at the intersection of national-security need and pharmaceutical innovation, pointing to the dual revenue stream from DoD hypersonic testing and drug manufacturing that makes the bet unusual for a single company. Satellite Today reported that two W-series capsules had already returned to Earth in 2025 alone, in February and May, demonstrating the reentry cadence investors were underwriting.

The round's composition matters. Lux Capital and Founders Fund are deep-tech backers with long space-infrastructure track records; Khosla Ventures has backed several frontier manufacturing plays; Thiel's participation signals conviction that orbital pharma is a generational bet rather than a near-term flip. The syndicate structure spreads risk across investors comfortable with hardware-heavy, long-development-cycle companies, which is exactly what Varda is.

The $329 million total raises a question that the workforce side of the business will have to answer: at what point does orbital manufacturing require a labor pipeline that doesn't yet exist? The Series C is explicitly funding the lab and flight rate that will force that hiring to scale.

Why Huntsville? The Workforce Math Behind Varda's Alabama Expansion

Varda's decision to expand into Huntsville, Alabama is less a geographic curiosity than a workforce calculation — and it says something blunt about where orbital biotech manufacturing actually needs to hire.

Huntsville sits inside a corridor dense with aerospace engineering talent: NASA's Marshall Space Flight Center, the Army's Redstone Arsenal, and a supply chain built around rocket propulsion and defense systems. The workforce there already understands thermal protection, hypersonic environments, and mission-critical hardware. For Varda, that means a manufacturing and operations team can be built faster and cheaper than in El Segundo, where every embedded software engineer competes with the full weight of LA's tech economy for the same talent pool.

The expansion also signals a shift in the company's operational model. El Segundo handles the hardware design and software architecture. Huntsville is where those designs become repeatable production, where capsules get built, tested, and prepared for launch at a cadence that matches a real pharmaceutical pipeline rather than a demonstration schedule. That demands a different workforce: manufacturing technicians who can work to pharmaceutical-grade process controls, quality engineers who understand both aerospace tolerances and FDA-adjacent documentation standards, and mission operators who manage the cadence of capsule builds, launches, reentries, and handoffs on a timeline measured in weeks, not years.

The practical effect is that Varda is building two distinct workforce clusters. California stays the engineering brain. Alabama becomes the industrial body. Companies that Zero G Talent tracks across orbital manufacturing (Sierra Space with its 22 new roles across Colorado and Wisconsin, for example) tend to concentrate in one location. Varda's split suggests it expects the ground-side production workforce to grow faster than the design team, which is what you'd anticipate if the United Therapeutics deal and the sixth reentry have actually converted the company from a startup proving a concept into one building a factory.

The question the Huntsville facility answers isn't whether orbital pharmaceutical manufacturing works. The sixth reentry already addressed that Varda can staff the team to do it at pharmaceutical scale, and whether the talent market outside the coastal tech hubs can support that build. The facility is the bet that it can.

Hypergravity Screening: The Ground-Side Moat

Before a drug ever reaches orbit, Varda runs it through a hypergravity screening platform on the ground: a centrifuge-based system that exposes compounds to elevated gravity levels to measure how they behave as gravitational force changes. The company observes and quantifies gravity-dependent drug product metrics as a function of gravity: polymorph ratio changes, and other formulation variables that correlate with what the same compound will do in microgravity. The output is a process model that treats gravity as an explicit variable, letting Varda predict which molecules are worth the cost of an orbital run.

This matters because orbital manufacturing slots are scarce and expensive. Every capsule launch carries a fixed payload budget, and sending the wrong compound to orbit wastes both the flight and the reentry window. Hypergravity screening acts as a filter, a way to derisk compound selection before committing to a mission.

The workforce implication is specific. Building and operating a hypergravity screening platform requires formulation scientists who understand both pharmaceutical processing and gravitational physics, a combination that doesn't exist in most biotech hiring pipelines. Varda's job board reflects this: the company is hiring controls and automation software engineers, embedded software engineers, and space mission operations engineers in El Segundo, roles that sit at the intersection of pharmaceutical process control and spacecraft systems. These aren't generic biotech positions. They're a new category: people who can run a drug development pipeline where one of the process variables is the gravitational environment itself.

That's the moat. Competitors can build orbital capsules. What's harder to replicate is the ground-side screening infrastructure that tells you which compounds to send up and why. Varda's hypergravity platform gives it a proprietary dataset on gravity-dependent drug behavior, data that compounds with each mission and makes the orbital manufacturing thesis harder for a new entrant to copy from scratch.

Can the FDA Regulate a Factory That Flies?

No space-manufactured drug has ever received FDA approval. That single fact defines the regulatory challenge facing every company building orbital biotech — and it is the reason Varda's workforce thesis ultimately lives or dies on a timeline that stretches years beyond its current reentry cadence.

The FDA's existing framework for drug approval operates through a sequence codified in Title 21 of the Code of Federal Regulations: an Investigational New Drug application (IND) before human trials, followed by three clinical phases, then a New Drug Application (NDA) or Biologics License Application (BLA). The IND alone requires preclinical safety data, clinical protocols, investigator qualifications, and chemistry, manufacturing, and control (CMC) information, the manufacturing section being the first serious friction point for a company whose factory operates in microgravity. The FDA's CGMP regulations under 21 CFR Parts 210 and 211 set minimum requirements for manufacturing methods, facilities, and controls. Those rules were written for terrestrial factories, not capsules that experience vibration profiles ranging from launch loads to microgravity during production to hypersonic reentry.

The FDA has shown some willingness to accommodate novel production. Its Advanced Manufacturing Technologies Designation Program, finalized in guidance issued jointly by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research, creates a pathway for manufacturers using novel production methods to get early agency engagement. That program does not specifically address orbital manufacturing, but it establishes a procedural precedent: the FDA will work with companies using non-traditional production environments if the data package demonstrates product quality and patient safety.

The chemistry, manufacturing, and controls section of any IND submission would need to demonstrate that a drug produced in orbit meets identity, strength, quality, and purity standards equivalent to a terrestrial product. That means Varda or its pharmaceutical partners would need to show that microgravity crystallization or bioprocessing produces a characterized, stable product, and that the manufacturing process is reproducible across missions with different thermal, radiation, and vibration profiles. Each reentry mission varies slightly. The agency will want statistical process control data that proves those variations do not affect the drug.

Clinical timelines add years on top of the manufacturing challenge. Orbital Intel's analysis projects that the first space-manufactured pharmaceuticals could enter clinical trials by 2028 or 2029, with commercial availability potentially by 2030 or 2031, assuming successful demonstration missions and regulatory approval. That estimate lines up with the broader drug development timeline, which averages 10 to 15 years from discovery to approval for conventional therapies, though expedited pathways like priority review or accelerated approval could compress treatments.

The United Therapeutics partnership gives Varda a plausible shortcut on the clinical side. If the microgravity-produced compound is a reformulation of an already-approved therapeutic, the partners could pursue a 505(b)(2) application under 21 CFR 314, which allows reliance on existing safety and efficacy data for the reference drug. That pathway avoids repeating large clinical trials and shortens the review cycle. It also means the manufacturing question becomes comparative: does the space-made version perform as well as or better than the ground-made version? That is a lower bar than proving safety from scratch, but it still requires a rigorous CMC package and bridging studies.

The UK is moving faster on the regulatory side, which creates competitive pressure. In March 2026, the UK Space Agency, the Medicines and Healthcare products Regulatory Agency, and the Civil Aviation Authority announced a coordinated package to support in-orbit pharmaceutical manufacturing, including regulatory guidance, case studies, and a re-entry regulatory sandbox. Lawrence Tallon, CEO of the MHRA, said the agency's 2025 framework for decentralized and modular manufacturing already accommodates production in microgravity. That framework, designed for small-scale, mobile manufacturing units on Earth, is being adapted for orbital use. The MHRA is working directly with BioOrbit, a startup developing a system to crystallize biologic drugs in orbit, to generate case studies that will serve as templates for future applicants. If the UK clears a space-made drug before the FDA does, it sets a regulatory precedent the agency would have to reckon with.

Varda's hiring signals where it thinks the long game is heading. The company's open roles include Space Mission Operations Engineers and Senior Embedded Software Engineers in El Segundo, positions that suggest Varda is building the operational backbone to run pharmaceutical production sequences autonomously in orbit, not just fly capsules. Every mission that produces a candidate compound under controlled, documented conditions builds the dataset that an IND submission will eventually require. The sixth reentry proved the return works. The next phase of missions needs to prove the product works, consistently, mission after mission, with enough process data to satisfy an FDA reviewer who has never evaluated a factory that flies.

The workforce implication is clear: Varda will need regulatory affairs specialists who understand both FDA submission frameworks and spaceflight operations. That is a hiring category that barely exists today. Building it is as much a part of the orbital manufacturing bet as the capsule itself.

Who Else Orbital Biotech?

Varda does not operate in a vacuum. A handful of companies are racing to build the infrastructure and the workforce for orbital pharmaceutical manufacturing, and the differences in their approaches matter for anyone considering a career in the sector.

Redwire is the most direct competitor in pharma. The Jacksonville-based company, now NYSE-listed, operates the PIL-BOX crystallization platform on the International Space Station and has flown 54 units, testing 37 drug compounds for Eli Lilly, Bristol Myers Squibb, and others, CNBC reported. Last year Redwire spun out SpaceMD as a dedicated subsidiary to commercialize space-developed pharmaceuticals. But Redwire's model depends on the ISS, which is scheduled for deorbit in 2030. That timeline forces SpaceMD to establish relationships with commercial station providers like Vast and StarLab, a transition that creates uncertainty for a workforce trained on government-platform operations.

Sierra Space is taking a different path. The company is qualifying its LIFE inflatable habitat and flying its Dream Chaser winged cargo spaceplane, which lands on conventional runways and keeps reentry loads under 1.5 g, a meaningful advantage for fragile bioprinted scaffolds that cannot survive a capsule's 4-g deceleration. Sierra Space is also the anchor tenant for the planned Orbital Reef commercial station with Blue Origin. The company added 22 roles to Zero G Talent's board in the past week alone, including senior project engineers and RF engineers, suggesting active hiring for its station and spaceplane programs.

Axiom Space is building what it calls Axiom Hub One, a commercial node that docks to the ISS before detaching ahead of the station's deorbit to become the first free-flying commercial station. The company has already flown four private astronaut missions with biomedical payloads and is NASA's primary partner for Commercial LEO Destinations. BioServe, based at the University of Colorado Boulder, runs the CGBA and ADSEP incubators that have hosted commercial biology on the ISS since the Shuttle era, the de-risked entry point most pharma programs use before scaling to a Varda capsule or an Axiom node.

Then there is Space Forge, a Cardiff-based startup developing reusable ForgeStar capsules for semiconductor materials, and a layer of newer entrants (Inversion Space, Atmos Space Cargo, Stoke Space) building dedicated reentry capsules and reusable launchers to compete on downmass.

Varda's distinction is integration. It designs and builds its own orbital manufacturing satellites, 300-kilogram autonomous labs on a Rocket Lab Photon bus, and its own heat-shielded reentry capsules, which land in the Utah Test and Training Range and Koonibba, South Australia under an FAA Part 450 license. That end-to-end control means Varda hires across a stack that no other pharma-focused company matches: mission operations, reentry thermal protection, autonomous navigation, ground systems, and cGMP-compliant manufacturing engineering all under one roof.

The workforce implication is concrete. Redwire and BioServe need ISS payload specialists and station operations engineers. Sierra Space needs spaceplane and inflatable-habitat structural engineers. Axiom needs commercial station systems integrators. Varda needs people who can build and operate an autonomous pharmaceutical factory that survives hypersonic reentry, a skill set that does not yet exist in any terrestrial industry and that the company is hiring for now, in El Segundo and Huntsville, at salary bands from $120,000 to $216,000 a year.

Working in frontier tech? Zero G Talent tracks the openings: browse frontier tech jobs, openings at Sierra Space, Varda Space and Sierra AI, and the people building the field.